Detalhe da pesquisa
1.
The Molecular Tumor Board of the Regina Elena National Cancer Institute: from accrual to treatment in real-world.
J Transl Med
; 21(1): 725, 2023 10 16.
Artigo
em Inglês
| MEDLINE | ID: mdl-37845764
2.
A prognostic score from a multicentric retrospective analysis of patients affected by sarcoma with metachronous lung metastases undergoing metastasectomy.
J Surg Oncol
; 127(6): 1035-1042, 2023 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-36807911
3.
Phase 2 study for nonmetastatic extremity high-grade osteosarcoma in pediatric and adolescent and young adult patients with a risk-adapted strategy based on ABCB1/P-glycoprotein expression: An Italian Sarcoma Group trial (ISG/OS-2).
Cancer
; 128(10): 1958-1966, 2022 05 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-35201621
4.
Neoadjuvant chemotherapy in high-risk soft tissue sarcomas: A Sarculator-based risk stratification analysis of the ISG-STS 1001 randomized trial.
Cancer
; 128(1): 85-93, 2022 Jan 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-34643947
5.
Prognostic value of total metabolic tumour volume and therapy-response assessment by [18F]FDG PET/CT in patients with metastatic melanoma treated with BRAF/MEK inhibitors.
Eur Radiol
; 32(5): 3398-3407, 2022 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-34779873
6.
Malignant Transformation of Giant Cell Tumour of Bone: A Review of Literature and the Experience of a Referral Centre.
Int J Mol Sci
; 23(18)2022 Sep 14.
Artigo
em Inglês
| MEDLINE | ID: mdl-36142631
7.
[18F]FDG PET/CT quantitative parameters for the prediction of histological response to induction chemotherapy and clinical outcome in patients with localised bone and soft-tissue Ewing sarcoma.
Eur Radiol
; 31(9): 7012-7021, 2021 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-33715090
8.
Symptoms and their implications on quality of life and psychological distress in sarcoma patients.
Future Oncol
; 17(7): 817-823, 2021 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-33508959
9.
PTEN Function at the Interface between Cancer and Tumor Microenvironment: Implications for Response to Immunotherapy.
Int J Mol Sci
; 21(15)2020 Jul 27.
Artigo
em Inglês
| MEDLINE | ID: mdl-32727102
10.
Prolonged Survival in Stage III Melanoma with Ipilimumab Adjuvant Therapy.
N Engl J Med
; 375(19): 1845-1855, 2016 11 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-27717298
11.
Sarcoma patients' quality of life from diagnosis to yearly follow-up: experience from an Italian tertiary care center.
Future Oncol
; 15(27): 3125-3134, 2019 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-31512484
12.
Nilotinib in locally advanced pigmented villonodular synovitis: a multicentre, open-label, single-arm, phase 2 trial.
Lancet Oncol
; 19(5): 639-648, 2018 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-29571946
13.
Fibrous dysplasia: an unusual case of a very aggressive form with costo-vertebral joint destruction and invasion of the contralateral D7 vertebral body.
Skeletal Radiol
; 47(11): 1571-1576, 2018 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-29789859
14.
Intralesional vs. extralesional procedures for low-grade central chondrosarcoma: a systematic review of the literature.
Arch Orthop Trauma Surg
; 138(7): 929-937, 2018 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-29633075
15.
Health-related quality of life with adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): secondary outcomes of a multinational, randomised, double-blind, phase 3 trial.
Lancet Oncol
; 18(3): 393-403, 2017 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-28162999
16.
Histotype-tailored neoadjuvant chemotherapy versus standard chemotherapy in patients with high-risk soft-tissue sarcomas (ISG-STS 1001): an international, open-label, randomised, controlled, phase 3, multicentre trial.
Lancet Oncol
; 18(6): 812-822, 2017 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-28499583
17.
Ipilimumab 10 mg/kg versus ipilimumab 3 mg/kg in patients with unresectable or metastatic melanoma: a randomised, double-blind, multicentre, phase 3 trial.
Lancet Oncol
; 18(5): 611-622, 2017 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-28359784
18.
Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma.
N Engl J Med
; 371(20): 1877-88, 2014 Nov 13.
Artigo
em Inglês
| MEDLINE | ID: mdl-25265492
19.
Correction to: Prognostic value of total metabolic tumour volume and therapy-response assessment by [18F]FDG PET/CT in patients with metastatic melanoma treated with BRAF/MEK inhibitors.
Eur Radiol
; 32(8): 5783, 2022 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-35262771
20.
Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial.
Lancet
; 386(9992): 444-51, 2015 Aug 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-26037941